Guidant MADIT II Trial Could Support Doubling Of ICD-Eligible Population

Favorable results of the Guidant-sponsored MADIT II trial could increase the U.S. patient population that could benefit from implantable cardioverter defibrillator therapy from 300,000 to about 600,000, Guidant says